• Publications
  • Influence
Management of acne: a report from a Global Alliance to Improve Outcomes in Acne.
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
This update reviews new information about acne pathophysiology and treatment-such as lasers and light therapy-and relevant topics where published data were sparse in 2003 but are now available including combination therapy, revision of acne scarring, and maintenance therapy.
Postmenopausal hormone therapy: an Endocrine Society scientific statement.
A scholarly review of the published literature on menopausal hormonal therapy (MHT), make scientifically valid assessments of the available data, and grade the level of evidence available for each clinically important endpoint to arrive at major conclusions.
Guidelines of care for acne vulgaris management.
The ultimate judgment regarding the propriety of any specific therapy must be made by the physician and the patient in light of all the circumstances presented by the individual patient.
Human skin is a steroidogenic tissue: steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1).
Data demonstrate that the skin is in fact a steroidogenic tissue and the clinical significance of this finding in mediating androgenic skin disorders such as acne, hirsutism, or androgenetic alopecia remains to be established.
Cutaneous androgen metabolism: basic research and clinical perspectives.
The skin, especially the pilosebaceous unit composed of sebaceous glands and hair follicles, can synthesize androgens de novo from cholesterol or by locally converting circulating weaker androgens to
Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee
An updated standard classification of rosacea is proposed that is based on phenotypes linked to the increased understanding of disease pathophysiology to provide clearer parameters to conduct investigations, guide diagnosis, and improve treatment.
The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
D doses of finasteride as low as 0.2 mg per day maximally decreased both scalp skin and serum DHT levels, which support the rationale used to conduct clinical trials in men with male pattern hair loss at doses of Finasteride between 0.
IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway.
Data indicate that IGF-1 transmits its lipogenic signal in sebocytes through activation of Akt, and specific targeted interruption of this pathway in the sebaceous gland could be a desirable approach to reducing sebum production and improving acne.
Finasteride in the treatment of men with frontal male pattern hair loss.
In men with hair loss in the anterior/mid area of the scalp, finasteride 1 mg/day slowed hair loss and increased hair growth.